276 Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy.

275 Targeted anti–IL-1β platelet microparticles for cardiac detoxing and repair.

274 Cardiac stem cell therapy in mouse models of ischaemia–reperfusion injury demonstrates that improvement in heart function is linked to an immune response characterized by the induction of CCR2+ and CX3CR1+ macrophages.

273 Alcohol Abstinence in Drinkers with Atrial Fibrillation.

272 A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.

271 Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.

270 Restraining cardiotoxic T cells through manipulation of the microbiome transforms inflammatory cardiomyopathy into a targetable disease.

269 Platelet-induced myeloid Socs3 expression in humans and mice contributes to unresolved atherosclerosis inflammation and sustained plaque growth.

268 Targeting cardiac fibrosis with engineered T cells.

267 Cell therapy in a rat model of heart attack is enhanced by stem-cell-derived epicardium.

Free Images for Presentation: sunipix SUNIPIX